Circulating pathogen associated molecular pattern-binding proteins and high mobility group box protein 1 in nascent metabolic syndrome: Implications for cellular toll-like receptor activity

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Jialal, I ^a,b   Rajamani, U ^a   Adams Huet, B ^c   Kaur, H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

HMGB 1; Metabolic syndrome; PAMP binding proteins; SCD14; Toll like receptors

Indexed keywords

BINDING PROTEIN; CD14 ANTIGEN; DAMAGE ASSOCIATED MOLECULAR PATTERN PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN BINDING PROTEIN; SOLUBLE CD14 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; AUTACOID; CARRIER PROTEIN; HMGB1 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; TLR4 PROTEIN, HUMAN;

ADULT; AGED; AORTA; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; METABOLIC SYNDROME X; MONOCYTE; NASCENT METABOLIC SYNDROME; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; CELL CULTURE; CHEMISTRY; DISEASE COURSE; INFLAMMATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY; RISK FACTOR; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTIGENS, CD14; AORTA; CARRIER PROTEINS; CELLS, CULTURED; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; NF-KAPPA B; RISK FACTORS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 84905833861     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.022     Document Type: Article

References (40)

1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
2. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
3. Kim C.H., Younossi Z.M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008, 75:721-728.
4. Hardy O.T., Kim A., Ciccarelli C., Hayman L.L., Wiecha J. Increased Toll-like receptor (TLR) mRNA expression in monocytes is a feature of metabolic syndrome in adolescents. Pediatr Obes 2013, 8:e19-23.
5. Jialal I., Huet B.A., Kaur H., Chien A., Devaraj S. Increased Toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012, 35:900-904.
6. Jialal I., Kaur H., Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. JClin Endocrinol Metab 2014, 99:39-48.
7. Su G.L., Dorko K., Strom S.C., Nussler A.K., Wang S.C. CD14 expression and production by human hepatocytes. JHepatol 1999, 31:435-442.
8. Kitchens R.L., Thompson P.A. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. JEndotoxin Res 2005, 11:225-229.
9. Pan Z., Zhou L., Hetherington C.J., Zhang D.E. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. JBiol Chem 2000, 275:36430-36435.
10. Pugin J., Schurer-Maly C.C., Leturcq D., Moriarty A., Ulevitch R.J., et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A 1993, 90:2744-2748.
11. Read M.A., Cordle S.R., Veach R.A., Carlisle C.D., Hawiger J. Cell-free pool of CD14 mediates activation of transcription factor NF-kappa B by lipopolysaccharide in human endothelial cells. Proc Natl Acad Sci U S A 1993, 90:9887-9891.
12. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
13. Fernandez-Real J.M., Perez del Pulgar S., Luche E., Moreno-Navarrete J.M., Waget A., et al. CD14 modulates inflammation-driven insulin resistance. Diabetes 2011, 60:2179-2186.
14. Johnson G.B., Riggs B.L., Platt J.L. Agenetic basis for the "Adonis" phenotype of low adiposity and strong bones. FASEB J 2004, 18:1282-1284.
15. Ogawa Y., Imajo K., Yoneda M., Kessoku T., Tomeno W., et al. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 2013, 8:e65211.
16. Schumann R.R. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans 2011, 39:989-993.
17. Tobias P.S., Mathison J.C., Ulevitch R.J. Afamily of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. JBiol Chem 1988, 263:13479-13481.
18. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., et al. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
19. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 2003, 31:785-790.
20. Gonzalez-Quintela A., Alonso M., Campos J., Vizcaino L., Loidi L., et al. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 2013, 8:e54600.
21. Moreno-Navarret J.M., Orteg F., Serino M., Luche E., Waget A., et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012, 36:1442-1449.
22. Sun L., Yu Z., Ye X., Zou S., Li H., et al. Amarker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010, 33:1925-1932.
23. Erlandsson Harris H., Andersson U. Mini-review: the nuclear protein HMGB-1 as a proinflammatory mediator. Eur J Immunol 2004, 34:1503-1512.
24. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB-1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
25. Hori O., Brett J., Slattery T., Cao R., Zhang J., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. JBiol Chem 1995, 270:25752-25761.
26. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002, 62:4805-4811.
27. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. JBiol Chem 2004, 279:7370-7377.
28. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290:C917-C924.
29. Jialal I., Devaraj S., Adams-Huet B., Chen X., Kaur H. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. JClin Endocrinol Metab 2012, 97:E1844-E1850.
30. Jialal I., Devaraj S., Singh U., Huet B.A. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis 2010, 211:297-302.
31. Dasu M.R., Devaraj S., Zhao L., Hwang D.H., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57:3090-3098.
32. Devaraj S., Dasu M.R., Park S.H., Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52:1665-1668.
33. Leber B., Tripolt N.J., Blattl D., Eder M., Wascher T.C., et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr 2012, 66:1110-1115.
34. Devaraj S., Chan E., Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. JClin Endocrinol Metab 2006, 91:4489-4496.
35. Ranoa D.R., Kelley S.L., Tapping R.I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. JBiol Chem 2013, 288:9729-9741.
36. Roncon-Albuquerque R., Moreira-Rodrigues M., Faria B., Ferreira A.P., Cerqueira C., et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sci 2008, 83:502-510.
37. Kelesidis T., Kendall M.A., Yang O.O., Hodis H.N., Currier J.S. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. JInfect Dis 2012, 206:1558-1567.
38. Reiner A.P., Lange E.M., Jenny N.S., Chaves P.H., Ellis J., et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 2013, 33:158-164.
39. Dasu M.R., Devaraj S., Park S., Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010, 33:861-868.
40. Sebekova K., Krivosikova Z., Gajdos M. Total plasma Nepsilon-(carboxymethyl) lysine and sRAGE levels are inversely associated with a number of metabolic risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clin Chem Lab Med 2014, 52:139-149.